Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Rostagno, R."'
Autor:
Pegbeliver, Study Group, Colombo, M, Facchetti, F, Massetto, B, Regep, L, Iannacone, C, Giuberti, T, Fargion, S, Farci, P, Boninsegna, S, Di Marco, V, Fasano, M, Sagnelli, E, Di Costanzo, Gg, Viganò, M, Lampertico, P, Andreone, P, Riili, A, Scuteri, A, Cursaro, C, Andriulli, A, Niro, Ga, Angarano, G, Santantonio, Ta, Palattella, Ms, Brunetto, MAURIZIA ROSSANA, Colombatto, P, Coco, B, Ciccorossi, P, Oliveri, F, Sacco, R, Bruno, S, Bollani, S, Chiesa, A, Carosi, G, Baiguera, C, Rossi, S, Zaltron, S, Puoti, M, Cozzolongo, R, Giannuzzi, V, Craxì, A, Calvaruso, V, Venezia, G, Lanza, Ag, Di Perri, G, Cariti, G, Mollaretti, O, De Blasi, T, Kulmiye, C, Rostagno, R, Lai, Me, Serra, G, Chessa, L, Balestrieri, C, Cauli, C, Fargion, Sr, Bertelli, C, Fatta, E, Fattovich, G, Pasino, M, Zanni, S, Olivari, N, Zagni, I, Ferrari, C, Schivazappa, S, Laccabue, D, Penna, A, Gaeta, G, Stanzione, M, Stornaiuolo, G, Martines, D, Raimondo, G, Caccamo, G, Squadrito, G, Isgrò, G, Rizzetto, M, Lagget, M, Carenzi, S, Ruggiero, G, Marrone, A, Messina, V, Di Caprio, Du, Selva, V, Toniutto, P.
Treatment with peginterferon α-2a (PegIFN) for 48 weeks is the standard of care for selected HBeAg-negative patients chronically infected with hepatitis B virus (HBV), but with limited treatment efficacy. A study was undertaken to investigate whethe
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2dee5413b7f9c6cb0e810d621c76720f
http://hdl.handle.net/11568/844307
http://hdl.handle.net/11568/844307
Autor:
Luca Mologni, Roberta Rostagno, Michela Viltadi, Vera Magistroni, Rocco Piazza, Carlo Gambacorti-Passerini, Daniel L. Flynn, Sara Redaelli, Monica Ceccon
BCR/ABL (Breakpoint Cluster Region protein/Abelson tyrosine-protein kinase 1) kinase domain (KD) mutations represent the most frequently described mechanism of resistance to the treatment with tyrosine kinase inhibitors (TKI) in patients with chronic
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1f22478145c4e1c6d473505e7a24b59a
http://hdl.handle.net/10281/53754
http://hdl.handle.net/10281/53754
Autor:
Michela Viltadi, Rocco Piazza, Roberta Rostagno, Carlo Gambacorti-Passerini, Sara Redaelli, Daniel L. Flynn, Luca Mologni, Scott C. Wise
Abstract 3398 Chronic Myeloid Leukemia (CML) treatment was radically modified by the discovery of imatinib (IM), a selective inhibitor of the fusion kinase Bcr-Abl. Second generation ATP-competitive tyrosine kinase inhibitors (TKIs) bosutinib (BOS),
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::11d93c6e6f5db26abd3922b3050f5fc7
http://hdl.handle.net/10281/37566
http://hdl.handle.net/10281/37566
Autor:
Roberta Rostagno, Rocco Piazza, Leonardo Scapozza, Carlo Gambacorti-Passerini, Annamaria Galietta, Rosalind H. Gunby
Publikováno v:
The Lancet. Oncology. 4(2)
Imatinib (STI571 or CGP57148B) is an innovative treatment for tumours with a constitutively activated form of c-ABL, c-KIT, or PDGFR. Such tumours include Philadelphia-chromosome-positive (Ph-positive) leukaemias, gastrointestinal stromal tumours, an
Autor:
Carlo Gambacorti, Vera Magistroni, Sara Redaelli, Rocco Piazza, Roberta Rostagno, M Marega, Frank Boschelli, Marianna Sassone, Pietro Perini
Publikováno v:
Blood. 112:3220-3220
The treatment of Chronic Myeloid Leukemia (CML) has been radically modified by the discovery of imatinib (IM), a selective inhibitor of the fusion protein Bcr-Abl, the cause of the disease. A variable portion of CML patients experience resistance to